These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 26008605)
21. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. Ni HT; Spellman SR; Jean WC; Hall WA; Low WC J Neurooncol; 2001 Jan; 51(1):1-9. PubMed ID: 11349874 [TBL] [Abstract][Full Text] [Related]
22. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. Amoureux MC; Coulibaly B; Chinot O; Loundou A; Metellus P; Rougon G; Figarella-Branger D BMC Cancer; 2010 Mar; 10():91. PubMed ID: 20219118 [TBL] [Abstract][Full Text] [Related]
23. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells. Liu Y; Qureshi M; Xiang J Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168 [TBL] [Abstract][Full Text] [Related]
24. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy. Shin CA; Cho HW; Shin AR; Sohn HJ; Cho HI; Kim TG Oncotarget; 2016 Jul; 7(29):46173-46186. PubMed ID: 27323820 [TBL] [Abstract][Full Text] [Related]
25. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas. Vachher M; Arora K; Burman A; Kumar B J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121 [TBL] [Abstract][Full Text] [Related]
26. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Kikuchi T; Crystal RG Hum Gene Ther; 1999 May; 10(8):1375-87. PubMed ID: 10365667 [TBL] [Abstract][Full Text] [Related]
27. SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment. Moncayo G; Grzmil M; Smirnova T; Zmarz P; Huber RM; Hynx D; Kohler H; Wang Y; Hotz HR; Hynes NE; Keller G; Frank S; Merlo A; Hemmings BA Neuro Oncol; 2018 Apr; 20(5):621-631. PubMed ID: 29401256 [TBL] [Abstract][Full Text] [Related]
28. Collaborative overexpression of matrix metalloproteinase-1 and vascular endothelial growth factor-C predicts adverse prognosis in patients with gliomas. Xu Y; Zhong Z; Yuan J; Zhang Z; Wei Q; Song W; Chen H Cancer Epidemiol; 2013 Oct; 37(5):697-702. PubMed ID: 23870768 [TBL] [Abstract][Full Text] [Related]
30. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465 [TBL] [Abstract][Full Text] [Related]
31. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788 [TBL] [Abstract][Full Text] [Related]
32. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Prins RM; Soto H; Konkankit V; Odesa SK; Eskin A; Yong WH; Nelson SF; Liau LM Clin Cancer Res; 2011 Mar; 17(6):1603-15. PubMed ID: 21135147 [TBL] [Abstract][Full Text] [Related]
33. Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays. Nie S; Gurrea M; Zhu J; Thakolwiboon S; Heth JA; Muraszko KM; Fan X; Lubman DM J Proteome Res; 2015 Feb; 14(2):814-22. PubMed ID: 25469866 [TBL] [Abstract][Full Text] [Related]
34. RIZ1: a potential tumor suppressor in glioma. Zhang C; Zhu Q; He H; Jiang L; Qiang Q; Hu L; Hu G; Jiang Y; Ding X; Lu Y BMC Cancer; 2015 Dec; 15():990. PubMed ID: 26690953 [TBL] [Abstract][Full Text] [Related]
35. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Lemke D; Pfenning PN; Sahm F; Klein AC; Kempf T; Warnken U; Schnölzer M; Tudoran R; Weller M; Platten M; Wick W Clin Cancer Res; 2012 Jan; 18(1):105-17. PubMed ID: 22080438 [TBL] [Abstract][Full Text] [Related]
36. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026 [TBL] [Abstract][Full Text] [Related]
37. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. Lode HN; Xiang R; Pertl U; Förster E; Schoenberger SP; Gillies SD; Reisfeld RA J Clin Invest; 2000 Jun; 105(11):1623-30. PubMed ID: 10841521 [TBL] [Abstract][Full Text] [Related]
38. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. Zhang JG; Kruse CA; Driggers L; Hoa N; Wisoff J; Allen JC; Zagzag D; Newcomb EW; Jadus MR J Neurooncol; 2008 May; 88(1):65-76. PubMed ID: 18259692 [TBL] [Abstract][Full Text] [Related]
39. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector. Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669 [TBL] [Abstract][Full Text] [Related]
40. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]